Additional file 1: Table S1. of Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: a randomised controlled trial Mark Ng Tang Fui Luke Prendergast Philippe Dupuis Manjri Raval Boyd Strauss Jeffrey Zajac Mathis Grossmann 10.6084/m9.figshare.c.3629567_D1.v1 https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_Table_S1_of_Effects_of_testosterone_treatment_on_body_fat_and_lean_mass_in_obese_men_on_a_hypocaloric_diet_a_randomised_controlled_trial/4419296 Change in main outcomes compared to baseline within and between groups analysed by intention to treat. Figure S1. Circulating testosterone and luteinising hormone levels in placebo- and testosterone-treated men. Shown are (median, IQR) circulating total testosterone (TT) (A), calculated free testosterone (B) and luteinising hormone (C) levels at the indicated time points during the trial in men receiving placebo or testosterone, respectively. Circulating testosterone levels at 26 and 56 weeks represent trough levels, which were in the therapeutic trough range (10–15 nmol/L for TT) in testosterone-treated men. By contrast, testosterone levels at week 10 were obtained 4 weeks after injection of the study drug and represent a 4-week post injection peak, which is higher than the recommended trough range. Figure S2. Body weights in placebo and testosterone treated men. Shown are mean (95 % CI) body weights in kilogram in placebo- (grey line) and testosterone-treated men from baseline to 56 weeks. (PDF 321 kb) 2016-10-07 05:00:00 Testosterone Obesity Caloric restriction Body composition